Elsevier

Autoimmunity Reviews

Volume 12, Issue 1, November 2012, Pages 56-59
Autoimmunity Reviews

Review
Systemic juvenile idiopathic arthritis

https://doi.org/10.1016/j.autrev.2012.07.022Get rights and content

Abstract

Systemic juvenile idiopathic arthritis (sJIA) sets well apart from all the other forms of JIA. Several observations show that sJIA is etiopathogenically different from all the other forms of JIA and has a prominent autoinflammatory component. A major role in the pathogenesis is played by two proinflammatory cytokines, interleukin-6 and interleukin-1. The specific inhibition of these two cytokines is going to change not only the therapeutic approach to the disease but also, presumably, its long term prognosis.

Highlights

► sJIA is sets well apart from all the other forms of JIA. ► Autoinflammatory mechanisms seem to play a major role in the pathogenesis. ► IL-1 and IL-6 blockers are effective and will change the long term prognosis of JIA.

Introduction

Juvenile idiopathic arthritis (JIA) [1], [2] is not a disease but a term that gather together all forms of arthritis which begin before the age of 16 years, persist for more than 6 weeks, and are of unknown etiology. It is, therefore, an exclusion diagnosis that includes all forms of childhood chronic arthritis of unknown cause. This heterogeneous group of disorders has been classified on clinical and laboratory features to try to identify homogeneous, mutually exclusives categories. Systemic JIA (sJIA) sets well apart from all the other forms of JIA for the presence, beside arthritis, of prominent systemic features and a marked inflammatory response. The last decade has witnessed important changes in the understanding of this disease and in its therapeutic approach [2], [3].

Section snippets

Clinical features

What characterizes sJIA [1], [2] is the presence of a quotidian, high spiking fever often associated with an evanescent, non-fixed, erythematous rash. Myalgias and abdominal pain may be intense during fever peaks. Other systemic features include hepato-splenomegaly, generalized lymphoadenopathy, and serositis. Laboratory examinations show a prominent inflammatory response characterized by leukocytosis (with neutrophilia), high erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)

Pathogenesis

Laboratory observations in the last 20 years and the therapeutic results obtained with biological agents have deeply changed our understanding of the pathogenesis of sJIA as well as its treatment. The systemic features, the marked inflammatory response, the lack of sex bias, peak age at onset, and association with autoantibodies are all consistent with what is observed in autoinflammatory diseases. Moreover, laboratory and clinical observations have shown a major pathogenic role of the innate

Treatment

In the first few weeks, during the diagnostic workup period, patients are treated with nonsteroidal anti-inflammatory drugs. Once the diagnosis is made and if symptoms persist, as is often the case, steroid therapy is indicated. Usually 2 mg/kg of prednisone has a rapid effect on symptoms and laboratory abnormalities. Treatment with prednisone does not affect disease duration or long term outcome and, in the long run, is associated with severe side effects. If a chronic steroid therapy is needed

Conclusions

There is an emerging consensus that sJIA disease should be viewed as an autoinflammatory syndrome rather than a classic auto-immune disease. This is especially true for those patients that exhibit a response to IL-1 blocking agents as spectacular as that observed in cryopyrinopathies.

It is probable that sJIA does not represent a single disease but as monogenic autoinflammatory diseases, a syndrome that represents the common final pathway of potential different causes all leading to a persistent

References (32)

  • H. Wissler

    Subsepsis hyperergica

    Monatsschr Kinderheilkd

    (1943)
  • F. De Benedetti et al.

    Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis

    Arthritis Rheum

    (1991)
  • E. Nemeth et al.

    IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin

    J Clin Invest

    (2004)
  • F. De Benedetti et al.

    Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation

    J Clin Invest

    (1997)
  • F. De Benedetti et al.

    Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease?

    J Rheumatol

    (1998)
  • J.W. Verbsky et al.

    Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis

    J Rheumatol

    (2004)
  • Cited by (95)

    • Autoimmune diseases

      2022, Clinical Immunology
    • Are there new targets for juvenile idiopathic arthritis?

      2019, Seminars in Arthritis and Rheumatism
    • Juvenile Idiopathic Arthritis

      2024, Indian Journal of Pediatrics
    View all citing articles on Scopus
    View full text